NEW YORK, NY / ACCESS Newswire / November 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Hormel Foods Corporation ("Hormel Foods Corporation") (NYSE:HRL) concerning possible violations of federal securities laws. The Wall Street Journal published an article on October 29, 2025, entitled "Hormel Cuts Forecast on Price Pressure, […]
NEW YORK, NY / ACCESS Newswire / November 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. ("Protalix" or the "Company") (NYSE:PLX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Protalix and certain of its officers and/or directors
NEW YORK, NY / ACCESS Newswire / November 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Beyond Meat, Inc. ("Beyond Meat" or the "Company") (NASDAQ:BYND). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Beyond Meat and certain of its officers
NEW YORK, NY / ACCESS Newswire / November 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stride, Inc. ("Stride, Inc.") (NYSE:LRN) concerning possible violations of federal securities laws. On October 28, 2025, Stride reported its first quarter fiscal 2026 earnings after market. While earnings beat expectations, enrollment numbers
NEW YORK, NY / ACCESS Newswire / November 9, 2025 / If you suffered a loss on your Synopsys, Inc. (NASDAQ:SNPS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/synopsys-inc-lawsuit-submission-form?prid=176283&wire=1&utm_campaign=27 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call
London, UK, Boston, MA, 9 November 2025 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, today presented long-term efficacy and safety data from a 52-week open-label extension of its pivotal Phase 3 study in treatment-naive patients with hypertension. In this 52-week follow-up period of 50 subjects, treatment
George Medicines presents long-term efficacy and safety data for single pill triple combination therapy for hypertension at American Heart Association's Scientific Sessions 2025 GlobeNewswire November 09, 2025 London, UK, Boston, MA, 9 November 2025 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, today presented long-term efficacy and
NEW YORK, NY / ACCESS Newswire / November 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stride, Inc. ("Stride, Inc.") (NYSE:LRN) concerning possible violations of federal securities laws. On October 28, 2025, Stride reported its first quarter fiscal 2026 earnings after market. While earnings beat expectations, enrollment numbers
NEW YORK, NY / ACCESS Newswire / November 9, 2025 / If you suffered a loss on your aTyr Pharma, Inc. (NASDAQ:ATYR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/atyr-pharma-inc-lawsuit-submission-form?prid=176262&wire=1&utm_campaign=26 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or
NEW YORK, NY / ACCESS Newswire / November 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Savers Value Village, Inc. ("Savers" or the "Company") (NYSE:SVV). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Savers and certain of its officers and/or